lifestyle.cfxmagazine.com

Author: BIOHAVEN LTD

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

March 3, 2026
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

January 14, 2026
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

January 14, 2026
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

January 12, 2026
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

January 12, 2026
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

December 24, 2025
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

November 16, 2025
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

November 15, 2025